Indivior PLC (INDV)
NASDAQ: INDV · IEX Real-Time Price · USD
17.87
+0.09 (0.51%)
May 9, 2024, 4:30 PM EDT - Market closed
Indivior Employees
Indivior had 1,164 employees on December 31, 2023. The number of employees increased by 211 or 22.14% compared to the previous year.
Employees
1,164
Change (1Y)
211
Growth (1Y)
22.14%
Revenue / Employee
$965,636
Profits / Employee
$4,296
Market Cap
2.42B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,164 | 211 | 22.14% |
Dec 31, 2022 | 953 | 68 | 7.68% |
Dec 31, 2021 | 885 | 66 | 8.06% |
Dec 31, 2020 | 819 | -96 | -10.49% |
Dec 31, 2018 | 915 | -108 | -10.56% |
Dec 31, 2017 | 1,023 | 58 | 6.01% |
Dec 31, 2016 | 965 | 80 | 9.04% |
Dec 31, 2015 | 885 | 157 | 21.57% |
Dec 31, 2014 | 728 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Patterson Companies | 7,600 |
Premier | 2,800 |
PTC Therapeutics | 995 |
Twist Bioscience | 919 |
Denali Therapeutics | 445 |
Arvinas | 445 |
RxSight | 374 |
Vericel | 314 |
INDV News
- 15 days ago - Indivior Announces Q1 2024 Financial Results - PRNewsWire
- 2 months ago - Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone - PRNewsWire
- 2 months ago - Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation - PRNewsWire
- 2 months ago - Drugmaker Indivior consults on moving primary listing from London to US - Reuters
- 2 months ago - Indivior Announces Q4 / FY 2023 Financial Results - PRNewsWire
- 6 months ago - Indivior Announces Q3 2023 Financial Results - PRNewsWire
- 7 months ago - Indivior to pay $385 mln to end Suboxone monopoly lawsuits - Reuters
- 7 months ago - Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals - PRNewsWire